BRCA1 and cancer: These three BRCA1/2 founder mutations are identified in approximately 2%-2.5% of unselected AJ individuals.9 One study showed that in individuals of AJ descent, these three founder mutations account for 87% and 92.8% of the mutations in BRCA1 and BRCA2, respectively.10 However, these three mutations account for the minority of PLPV in BRCA1/2 in the non-AJ population.11 This leads to the concern that individuals who order these tests may have a false sense of security regarding their cancer risk upon receiving a negative DTC test result.